Evidence map›Paper›PMID 27152762›Full record

ReviewExpert review of neurotherapeutics2016

Growth factor therapy sequesters inflammation in affording neuroprotection in cerebrovascular diseases.

Hung Nguyen, David Aum, Sherwin Mashkouri, Gautam Rao, Juan Diego Vega Gonzales-Portillo, Stephanny Reyes, Cesario V Borlongan

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Expert review of neurotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. An update on stem cell therapy for stroke patients: Where are we now?Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2024
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Eye Opener in Stroke.Stroke · 2019
    Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hung Nguyena Department of Neurosurgery and Brain Repair , University of South Florida Morsani College of Medicine , Tampa , FL , USA.
David Auma Department of Neurosurgery and Brain Repair , University of South Florida Morsani College of Medicine , Tampa , FL , USA.
Sherwin Mashkouria Department of Neurosurgery and Brain Repair , University of South Florida Morsani College of Medicine , Tampa , FL , USA.
Gautam Raoa Department of Neurosurgery and Brain Repair , University of South Florida Morsani College of Medicine , Tampa , FL , USA.
Juan Diego Vega Gonzales-Portilloa Department of Neurosurgery and Brain Repair , University of South Florida Morsani College of Medicine , Tampa , FL , USA.
Stephanny Reyesa Department of Neurosurgery and Brain Repair , University of South Florida Morsani College of Medicine , Tampa , FL , USA.
Cesario V Borlongana Department of Neurosurgery and Brain Repair , University of South Florida Morsani College of Medicine , Tampa , FL , USA.
University of South Florida · US

Funding

Blood-Brain Barrier Repair in Cell Therapy for StrokeR01NS071956 · NINDS · UNIVERSITY OF SOUTH FLORIDA · PI BORLONGAN, CESARIO V, GARBUZOVA-DAVIS, SVITLANA NICOLAI · 2011 to 2015
$2.1M
Re-Establishing Vascular Integrity in ALS via Endothelial Cell TransplantR01NS090962 · NINDS · UNIVERSITY OF SOUTH FLORIDA · PI BORLONGAN, CESARIO V, GARBUZOVA-DAVIS, SVITLANA NICOLAI · 2015 to 2019
$1.6M
Vascular repair extends therapeutic window for ischemic strokeR21NS089851 · NINDS · UNIVERSITY OF SOUTH FLORIDA · PI BORLONGAN, CESARIO V · 2014 to 2015
$411k
NINDS NIH HHS R01 NS071956NINDS NIH HHS R01 NS090962NINDS NIH HHS R21 NS089851
6 · The paper itself

Abstract

introductionIn recent years, accumulating evidence has demonstrated the key role of inflammation in the progression of cerebrovascular diseases. Inflammation can persist over prolonged period of time after the initial insult providing a wider therapeutic window. Despite the acute endogenous upregulation of many growth factors after the injury, it is not sufficient to protect against inflammation and to regenerate the brain. Therapeutic approaches targeting both dampening inflammation and enhancing growth factors are likely to provide beneficial outcomes in cerebrovascular disease. AREAS COVERED: In this mini review, we discuss major growth factors and their beneficial properties to combat the inflammation in cerebrovascular diseases. Emerging biotechnologies which facilitate the therapeutic effects of growth factors are also presented in an effort to provide insights into the future combination therapies incorporating both central and peripheral abrogation of inflammation. Expert commentary: Many studies discussed in this review have demonstrated the therapeutic effects of growth factors in treating cerebrovascular diseases. It is unlikely that one growth factor can be used to treat these complex diseases. Combination of growth factors and anti-inflammatory modulators may clinically improve outcomes for patients. In particular, transplantation of stem cells may be able to achieve both goals of modulating inflammation and upregulating growth factors. Large preclinical studies and multiple laboratory collaborations are needed to advance these findings from bench to bedside.

Indexed as

Cerebrovascular DisordersNeuroprotectionBrainHumansInflammationIntercellular Signaling Peptides and ProteinsStem CellsIntercellular Signaling Peptides and Proteinsbiomedical engineeringCerebral ischemiagrowth factorsinflammationneuroprotectionstem cellstrauma

Identifiers

PMID27152762
PMCPMC5057178
OpenAlexW2346292204

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.